Phase
Condition
Pain (Pediatric)
Hypogonadism
Treatment
Testosterone Undecanoate 750 MG/3 ML Intramuscular Solution [AVEED]
placebo
Clinical Study ID
Ages 18-54 Male
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Cancer survivors who have received chemotherapy and/or radiation therapy for theircancer and are now in remission for at least one year
Non-hormone-dependent cancer, including most solid tumors, lymphomas and leukemias
Age: 18-54 years
Serum testosterone, measured by mass spectrometry (gold standard method), of <348ng/dl and/or free testosterone <70 pg/ml. The lower limits of the normal range fortotal testosterone in healthy young men (age 19-40 years), is 348 ng/dL and thelower limits of free testosterone is <70 pg/ml in the Framingham Heart Studysample97. Therefore, young symptomatic men with total testosterone <348 ng/dl couldbe considered testosterone deficient. As sex hormone binding globulin levels may beelevated in some men with cancer (resulting in elevation in total testosteronelevel), some of these symptomatic men may still be hypogonadal despite having totaltestosterone above this cut-off limit. However; their free testosterone levels maystill be below the lower limit of normal. Thus, we will also include men with freetestosterone <70 pg/mL.
Self-reported fatigue. We have selected these symptoms because they are commonlyreported in male cancer survivors. Fatigue will be defined as a score on FunctionalAssessment of Chronic Illness Therapy-Fatigue (FACIT-F) subscale of <40, which bestdivides cancer patients from the general population with 84% accuracy, and was usedas the cut-off for the NIA-funded 50-million-dollar testosterone trial (TheT-Trial).
Ability and willingness to provide informed consent.
Exclusion
Exclusion Criteria:
Men with hormone-dependent cancers (breast, prostate or adenocarcinoma of unknownorigin)
Men with brain cancer (potential cognitive impairment)
Use of anabolic agents (testosterone, dehydroepiandrosterone, growth hormone) withinthe past 6 months
Appetite stimulating agents e.g. megestrol acetate within the past 6 months
Systemic glucocorticoids e.g. prednisone 20 mg daily or equivalent doses of otherglucocorticoids for more than two weeks in the past 6 months
Baseline hematocrit >48%
PSA >4 ng/ml in Caucasians; >3 ng/ml in African-Americans
Men with 1st order relatives with a history of prostate cancer
Uncontrolled congestive heart failure
Severe untreated sleep apnea
Myocardial infarction, acute coronary syndrome, revascularization surgery, or strokewithin 3 months o Previous stroke with residual cognitive or functional deficits; Mini-Mental StateExamination score <24
Serum creatinine >2.5 mg/dL; ALT 3x upper limit of normal
Poorly controlled diabetes as defined by hemoglobin A1c >8.5%; Body mass index (BMI) >45 kg/m2
Untreated unipolar depression (treated depression with medications or counselingwill be allowed
Bipolar disorder or schizophrenia
Study Design
Study Description
Connect with a study center
Brigham and Women's Hospital
Boston, Massachusetts 02115
United StatesActive - Recruiting
Veterans Affairs Puget Sound Health Care System
Seattle, Washington 98108
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.